Artivion Inc (AORT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Artivion Inc stock (AORT) is currently trading at $35.70. Artivion Inc PE ratio is 168.14. Artivion Inc PS ratio (Price-to-Sales) is 3.83. Analyst consensus price target for AORT is $51.43. WallStSmart rates AORT as Sell.
- AORT PE ratio analysis and historical PE chart
- AORT PS ratio (Price-to-Sales) history and trend
- AORT intrinsic value — DCF, Graham Number, EPV models
- AORT stock price prediction 2025 2026 2027 2028 2029 2030
- AORT fair value vs current price
- AORT insider transactions and insider buying
- Is AORT undervalued or overvalued?
- Artivion Inc financial analysis — revenue, earnings, cash flow
- AORT Piotroski F-Score and Altman Z-Score
- AORT analyst price target and Smart Rating
Artivion Inc
📊 No data available
Try selecting a different time range
AORT Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Artivion Inc (AORT)
AORT trades 2704% above its Graham fair value of $1.43, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Artivion Inc (AORT) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around peg ratio and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Artivion Inc (AORT) Key Strengths (1)
92.15% of shares held by major funds and institutions
Supporting Valuation Data
Artivion Inc (AORT) Areas to Watch (8)
Very low returns on shareholder equity
Very expensive relative to growth, significant premium
Very thin margins with limited operational efficiency
Very thin margins, barely profitable
Premium pricing at 3.8x book value
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 3.83x sales
Solid revenue growth at 19.20% per year
Supporting Valuation Data
Artivion Inc (AORT) Detailed Analysis Report
Overall Assessment
This company scores 37/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 1 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 3.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, PEG Ratio, Operating Margin. Some valuation metrics including PEG Ratio (181.50), Price/Sales (3.83), Price/Book (3.77) suggest expensive pricing. Growth concerns include Revenue Growth at 19.20%, which may limit upside. Profitability pressure is visible in Return on Equity at 2.70%, Operating Margin at 8.09%, Profit Margin at 2.21%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 2.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 19.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and PEG Ratio are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AORT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AORT's Price-to-Sales ratio of 3.83x sits near its historical average of 3.91x (57th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 57% below its historical high of 8.88x set in Sep 2018, and 129% above its historical low of 1.67x in Nov 2011.
WallStSmart Analysis Synopsis
Data-driven financial summary for Artivion Inc (AORT) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Artivion Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 441M with 19% growth year-over-year. Profit margins are strong at 221.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 270.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -8M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Valuation compression risk at a P/E of 168.1x. Any growth miss could trigger a sharp correction.
Volatility is elevated with a beta of 1.64, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Artivion Inc.
Bottom Line
Artivion Inc offers an attractive blend of growth (19% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Artivion Inc(AORT)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.